Participated · Series A · Nov 2024

Toku is a Singapore-based, Asia-Pacific-focused provider of enterprise cloud communications and customer experience solutions. The company has operated since April 2018. Toku completed a $5 million Series A extension led by Betatron Venture Group, with participation from the Hong Kong Innovation and Technology Venture Fund (ITVF) and other investors. The injection brings the company’s total funding to $18 million. Management says the new capital will support continued international expansion. Toku also appointed former Singapore minister Chen Huihua as chair of its advisory board. Toku provides bespoke cloud communications and customer engagement solutions including Programmable APIs, Contact Centre and Corporate Telephony to help enterprises reimagine customer experience across APAC. The company combines local in‑country infrastructure, regional expertise and global reach to support digital transformation for businesses and government agencies. Toku works with regional brands such as foodpanda, Gojek, Lenskart, Decathlon and JCDecaux. It reported a compound annual growth rate (CAGR) of 128 percent over the past four years (including forecasted FY2022) and is closing in on half a billion customer interactions processed annually across 17 APAC markets. Toku plans to expand its local presence in Malaysia, Indonesia, Hong Kong, Vietnam, South Korea and the Philippines and aims to double headcount to about 200 by 2024. The company will continue to invest in innovation and technology to unify customer experience and employee experience into an all‑in‑one platform. Toku provides cloud communications solutions across UCaaS, CPaaS and communication APIs with native telco connectivity and integrations into tools like Microsoft Teams, HubSpot and Salesforce. The company is developing a hosted contact-centre (CCaaS) offering and aims to build an all-in-one platform combining CPaaS, UCaaS and CCaaS functionality. Toku will use the funding to enhance product capabilities, expand regional coverage and pursue strategic partnerships. It plans to develop its CCaaS solution over the next 18 months as part of broader product roadmap. The company intends to double its workforce in the next 12 months, adding more than 40 roles and opening additional offices across APAC. Founded in 2018 and headquartered in Singapore, Toku serves customers including Gojek, JCDecaux, Public Utilities Board Singapore and foodpanda.

Participated · Equity · Oct 2024

Meridian Innovation is a Singapore-based developer of low-cost, mass-producible thermal imaging sensors built on CMOS technology. Its core product is an advanced complementary metal-oxide-semiconductor (CMOS) LWIR thermal imaging sensor fabricated using a patented CMOS-only approach. The company targets commercial and consumer applications aimed at enabling safer and better living. Meridian has operations in Hong Kong, the USA and the UK and is led by CEO Hock Leow. It raised US$12.5M in the most recent funding round, bringing total funding to US$30M. The company intends to use the proceeds to scale operations, accelerate product development and expand into broader consumer and commercial markets. Meridian Innovation is a developer of low-cost, mass-manufacturable CMOS thermal sensors, marketed under its SenXor™ product family and protected by multiple international patents. Its sensors emphasize low power and low cost enabled by a CMOS production process and are positioned for rapid adoption across Smart Appliances, ADAS, AI-assisted failure analyzers, security, medical & safety products, and portable thermography instruments. Over the last 12 months Meridian has shipped to more than 20 customers across multiple market segments and has been manufacturing sensor modules for a year. The company is accelerating ramp-up of commercial production and working with a manufacturing investor to scale output. It is developing a second-generation SenXor™ sensor and plans to begin sampling that product in early 2022. Meridian has received steady investor support to date, bringing total investment to more than US$18 million. Meridian Innovation develops advanced CMOS thermal imaging solutions, using a patented approach to fabricate MEMS LWIR sensors. The company targets commercial and consumer markets including smart appliances, IoT devices, ADAS, AI-assisted heat-failure analyzers, security, and medical and safety products. Meridian plans to use new funding to further enable and accelerate market penetration and product development. It raised US$6M in its latest round, bringing total investment to date to more than US$10M. The company is led by CEO and co-founder Hock Leow and has operations in Singapore, Hong Kong, the USA and the UK. Meridian employs more than 25 people across its locations.

Participated · Series A · Apr 2024

引正基因 is a platform technology solutions provider focused on foundational gene‑editing tool development. The company develops next‑generation CRISPR‑based gene‑editing tools designed to improve editing efficiency and precision while reducing off‑target effects. It positions itself as a technology company building underlying capabilities for gene editing. The article reports the company completed a Pre‑A+ financing round of tens of millions of US dollars. Investors in the round include 晟德医药集团 and its 顺天医药, along with 启明创投, the Hong Kong SAR Innovation & Technology Venture Fund, and the Hong Kong Science Park Venture Fund. No operating metrics (revenue/users) or founding year are disclosed in the article.

Participated · Series B · Jul 2022

FreeD Group develops AI-driven chatbots, recommendation engines and Hybrid SaaS digital merchandising solutions for enterprise customers, including Samsung Electronics, Marriott International, Tencent, Singapore Telecommunications and China Mobile. Founded in 2015, the company combines AI, big data and machine learning to provide end-to-end AI digital transformation, smart merchandising and smart marketing services. FreeD has won multiple awards, including the 2021 Deloitte Technology Rising Star Award and the 2021 UNWTO Global Start-up Competition. It employs nearly 170 staff across 12 offices globally. The company’s software helps clients manage sales and marketing through customer-interaction and recommendation tools. In June 2022 FreeD completed a $15.0M Series B round to support growth and geographic expansion.

Participated · Series D · Jun 2021

HiFiBiO Therapeutics is a multinational biotherapeutics company that combines single-cell profiling, deep biological expertise, and data intelligence (DIS™) to discover and develop antibody drugs. Its core focus is differentiated antibody therapeutics for oncology and autoimmune disorders, with multiple discovery-stage programs and clinical candidates. The company will use proceeds from its oversubscribed $75M Series D to advance two lead oncology antibodies—HFB200301 (anti‑TNFR2) and HFB301001 (second‑generation anti‑OX40)—into Phase I trials and to continue discovery and clinical development. HiFiBiO also highlighted prior progress including rapid development of HFB30132A, a SARS‑CoV‑2 neutralizing antibody, into a Phase I trial (NCT04590430) and the launch of IND‑enabling studies and biomanufacturing for multiple antibodies. The company intends to validate its DIS™ approach and biomarker hypotheses in the clinic to enhance the probability of trial success for current and future programs. HiFiBiO operates laboratories across Cambridge, Mass.; Paris; Shanghai; Hong Kong; and Hangzhou, reflecting a global footprint. HiFiBiO Therapeutics operates a proprietary single-cell analytics platform (including CelliGO™) and Drug Intelligent Science (DIS™) to enable deep immune profiling and antibody discovery. The company integrates biological expertise with comprehensive single-cell technologies to identify precise patient subsets and novel biomarkers. HiFiBiO aims to advance multiple antibody drug candidates into clinical trials and accelerate pipeline development. It plans to use platform expansion to increase discovery throughput while reducing time and costs. The company has announced collaborations, an acquisition, a joint venture, and a Nature Genetics publication that demonstrate scientific and strategic progress. HiFiBiO maintains laboratories across Cambridge, Mass., Paris, France, and Shanghai, China. HiFiBiO Therapeutics develops antibody drugs by integrating deep biological expertise with single-cell profiling technologies and its proprietary single-B-cell functional antibody discovery CelliGOTM platform. The company is focused on advancing a pipeline of antibody therapeutics for cancer and autoimmune diseases and is establishing strategic partnerships with pharmaceutical and biotechnology companies to drive that pipeline. HiFiBiO operates more than 50 full-time employees across three facilities in the USA, France and China, with laboratories in Cambridge, MA and Hangzhou, China located within Nest.Bio Ventures incubator facilities. Liang Schweizer, PhD, serves as President and CEO, supported by a leadership team including Jeff He (COO), Colin Brenan, PhD (CCO) and Fred Dom (CFO). Financially, the company completed a $37.5M Series B financing in 2018 to support its discovery and development efforts. The company positions its proprietary platform and strategic partnerships as central to advancing its therapeutic pipeline.